LIDE Biotech: Translating Clinical Insight into Next-Generation, Predictive Tumor Models
- Clinically anchored tumor models: organoids, CDX, miniPDX, and >2,000-model PDX library preserving genomic integrity and therapeutic responsiveness
- Integrated biologics platforms for ADCs, T-cell engagers, and immuno-oncology agents assessing efficacy, toxicity, and immune responses
- Translational capabilities: target validation, biomarker discovery, PK/PD modeling, and in vivo pharmacology enabling data-driven decisions
- Human-relevant workflows reducing animal reliance while improving predictive power and program velocity